Recently Viewed
Clear AllQuality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹4,521 Cr
Revenue (TTM)
₹2,029 Cr
Net Profit (TTM)
₹151 Cr
ROE
-2.9 %
ROCE
-1.5 %
P/E Ratio
32.9
P/B Ratio
1.9
Industry P/E
45.47
EV/EBITDA
16.1
Div. Yield
0 %
Debt to Equity
0
Book Value
₹346
EPS
₹21.4
Face value
2
Shares outstanding
70,405,751
CFO
₹-457.32 Cr
EBITDA
₹175.89 Cr
Net Profit
₹-311.49 Cr
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
---|---|---|---|---|---|---|---|
Unichem Lab
| -13.7 | 1.1 | -6.7 | 13.1 | 38.5 | 38.4 | 12.4 |
BSE Healthcare
| -5.9 | 0.5 | 7.3 | 18.6 | 22.8 | 22.3 | 9.5 |
BSE Small Cap
| -6.0 | 4.8 | 12.4 | 7.4 | 25.0 | 37.4 | 16.5 |
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
---|---|---|---|---|---|---|---|
Unichem Lab
| 80.0 | 28.6 | 26.9 | -4.5 | 62.0 | -16.5 | -41.4 |
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
---|---|---|---|---|---|---|---|---|
Unichem Lab
|
642.0 | 4,521.1 | 2,028.9 | 150.6 | 7.5 | 6.2 | 32.9 | 1.9 |
474.2 | 4,327.1 | 2,387.0 | 168.1 | 9.7 | 12.7 | 25.7 | 3.2 | |
207.4 | 1,037.8 | 661.5 | 47.4 | 7.9 | 15.1 | 20.7 | 3.3 | |
302.6 | 3,296.7 | 150.8 | 48.8 | 42.1 | 20.7 | 67.6 | 13.3 | |
243.6 | 2,241.6 | 1,664.9 | -77.9 | -0.9 | -7.1 | -- | 2.2 | |
86.3 | 2,532.6 | 2,079.2 | 101.1 | 6.3 | 6 | 25.1 | 1.5 | |
66.6 | 3,646.6 | 1,811.6 | 118.0 | 8.0 | 10.4 | 30.9 | 3.2 | |
2,188.8 | 3,636.4 | 653.4 | 183.2 | 21.2 | 20.9 | 19.8 | 6.9 | |
476.7 | 2,292.4 | 1,283.8 | 0.5 | 8.3 | 0 | -- | 2.1 | |
207.7 | 4,526.1 | 6.7 | -160.8 | -2,578.1 | -106.2 | -- | 41.2 |
Are these companies really bargains?
2 min read•By Danish Khanna
Top contrary bets by FIIs and DIIs
5 min read•By Rajan Gulati
2 min read•By Yash Rohra
2 min read•By Value Research
4 min read•By Anindya Bera
2 min read•By Research Desk
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology,... psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, bulk drugs, and chemicals. Unichem Laboratories Limited was founded in 1944 and is based in Mumbai, India. Read more
Incorporated
1962
Chairman
Prakash A Mody
Managing Director
Pabitrakumar Kalipada Bhattacharyya
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Unichem Laboratories Ltd.’s IPO? Explore our IPO Details page.
Annual Reports
Announcements
View AnnouncementsResults For Quarter And Year Ended 2025
22-May-2025Board Meeting Outcome for Outcome
22-May-2025USFDA Inspection Report For Pithampur API Plant
14-May-2025The total asset value of Unichem Laboratories Ltd stood at ₹ 3,569 Cr as on 31-Mar-25
The share price of Unichem Laboratories Ltd is ₹642.00 (NSE) and ₹642.15 (BSE) as of 23-May-2025 IST. Unichem Laboratories Ltd has given a return of 38.45% in the last 3 years.
Unichem Laboratories Ltd has a market capitalisation of ₹ 4,521 Cr as on 23-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Unichem Laboratories Ltd is 1.86 times as on 23-May-2025, a 41% discount to its peers’ median range of 3.16 times.
The P/E ratio of Unichem Laboratories Ltd is 32.88 times as on 23-May-2025, a 28% discount to its peers’ median range of 45.47 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Unichem Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Unichem Laboratories Ltd.
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, bulk drugs, and chemicals. Unichem Laboratories Limited was founded in 1944 and is based in Mumbai, India.
The prominent promoters of Unichem Laboratories Ltd. are
Name of promoters | Holding percentage |
---|---|
Ipca Laboratories Limited |
52.67%
|
Dr. Prakash Amrut Mody |
12.78%
|
Anita Prakash Mody |
1.88%
|
Supriya Prakash Mody |
1.35%
|
The chairman of the company is Prakash A Mody, and the managing director is Pabitrakumar Kalipada Bhattacharyya.
There is no promoter pledging in Unichem Laboratories Ltd.
Some of the close peers are:
Company | Market Cap(₹ Cr) |
---|---|
4,526
|
|
4,327
|
|
3,647
|
|
3,636
|
|
3,297
|
|
2,533
|
|
2,292
|
|
2,242
|
|
1,038
|
Unichem Laboratories Ltd. | Ratios |
---|---|
Return on equity(%)
|
6.21
|
Operating margin(%)
|
7.55
|
Net Margin(%)
|
7.29
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Unichem Laboratories Ltd was ₹151 Cr.